Zydus Cadila gets USFDA approval to market generic schizophrenia drug Perphenazine

Zydus Cadila said it has 284 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of its filing process in the financial year 2003-2004.

FP Trending April 08, 2020 13:21:11 IST
Zydus Cadila gets USFDA approval to market generic schizophrenia drug Perphenazine

Pharma company Zydus Cadila has said it has received final approval from United States Food and Drug Administration (USFDA) to market generic Perphenazine tablets, used in the treatment of schizophrenia.

The drug is also used for the control of severe nausea and vomiting in adults.

USFDA has given its final nod to the company to market Perphenazine tablets USP in the strengths of 2 mg, 4 mg, 8 mg and 16 mg, Zydus Cadila said in a statement.

Zydus Cadila gets USFDA approval to market generic schizophrenia drug Perphenazine

Representative image. Image source: Pixabay

The USFDA is tasked with promoting public health through the control and supervision of several verticals including over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals and others.

“The drug will be manufactured at the group’s formulation manufacturing facility at Baddi [,” the statement added.

Zydus Cadila said it has 284 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of its filing process in the financial year 2003-2004.

On Tuesday, the pharma major announced on Twitter that it is producing Hydroxychloroquine, in large quantities to be used in the “treatment of coronavirus.” The company also said that it is working on developing a vaccine which will be a long term solution for COVID-19.

India on Tuesday decided to partially lift the ban on Hydroxychloroquine export, news agency PTI reported quoting officials.

US President Donald Trump had requested Prime Minister Narendra Modi to release the amount of Hydroxychloroquine ordered by the US after India on 25 March banned the export of the drug.

Updated Date:

also read

Over 9 cr COVID-19 samples tested in India, says health ministry; active cases below 8.3 lakh
India

Over 9 cr COVID-19 samples tested in India, says health ministry; active cases below 8.3 lakh

The national COVID-19 positivity rate is 8.04% and is on a 'continuous decline', said the health ministry on Wednesday

Italy going back to games with no fans in stadiums due to rising coronavirus cases
Sports

Italy going back to games with no fans in stadiums due to rising coronavirus cases

The new decree says professional games are allowed in outdoor venues “without fans in attendance.”

Lancet study finds COVID-19 reinfection possible, says more severe symptoms likely on relapse
Health

Lancet study finds COVID-19 reinfection possible, says more severe symptoms likely on relapse

The study said a 25-year old male patient was infected with two distinct SARS-CoV-2 variants within a 48-day time frame, while testing negative in between the infections